Effects of Crizotinib combined with AP chemotherapy in treatment of patients with advanced non-small cell lung cancer
Objective:To observe effects of Crizotinib combined with AP chemotherapy in treatment of patients with advanced non-small cell lung cancer.Methods:A prospective study was conducted on 80 patients with advanced non-small cell lung cancer admitted to the hospital from January 2022 to August 2023.According to the random number table method,they were divided into control group(n=40)and study group(n=40).The control group was treated with AP chemotherapy regimen,while the study group was treated with Crizotinib targeted therapy on the basis of that of the control group.The clinical efficacy,the serum tumor markers[carcinoembryonic antigen(CEA),tissue polypeptide antigen(TPA),neuron-specific enolase(NSE),cytokeratin fragment 19 antigen 21-1(CRYFRA21-1)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The objective remission rate of the study group was 82.50%(33/40),which was higher than 62.50%(25/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,TPA,NSE and CRYFRA21-1 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Crizotinib combined with AP chemotherapy in the treatment of the patients with advanced non-small cell lung cancer can improve the objective remission rate and reduce the levels of serum tumor markers.Moreover,it is superior to simple AP chemotherapy regimen.
万方数据
维普
